Recent Developments in Mendelian Randomization Studies.
Zheng J, Baird D, Borges MC, Bowden J, Hemani G, Haycock P, Evans DM, Smith GD. · 2017
Read Recent Developments in Mendelian Randomization Studies. by Zheng J, Baird D, Borges MC, Bowden J, Hemani G, Haycock P, Evans DM, Smith GD. (2017) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5711966.txt.
Introduction
Zheng and co-authors review recent developments in Mendelian randomization studies. Their review appeared in Current Epidemiology Reports. The method tests causality in observational data. It uses genes as natural instruments. Genes are fixed at conception. That shields them from reverse causation and confounding.
The review sets out core principles first. Assumptions and limits get frank treatment. Extensions of the basic method follow. Two-sample and multivariable designs are covered. Bidirectional and factorial variants appear too. New uses include drug development. Automation tools such as MR-Base are discussed. The authors see growing value in the method. Large genomic databases keep expanding its reach.
Catalog record
| CREATOR | Zheng J, Baird D, Borges MC, Bowden J, Hemani G, Haycock P, Evans DM, Smith GD. |
|---|---|
| YEAR | 2017 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 45 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Recent Developments in Mendelian Randomization Studies By Jie Zheng, Denis Baird, Maria-Carolina Borges, Jack Bowden, Gibran Hemani, Philip Haycock, David M. Evans, George Davey Smith Published in: Current Epidemiology Reports DOI: 10.1007/s40471-017-0128-6 ABSTRACT Purpose of Review Mendelian randomization (MR) is a strategy for evaluating causality in observational epidemiological studies. MR exploits the fact that genotypes are not generally susceptible to reverse causation and confounding, due to their fixed nature and Mendel’s First and Second Laws of Inheritance. MR has the potential to provide information on causality in many situations where randomized controlled trials are not possible, but the results of MR studies must be interpreted carefully to avoid drawing erroneous conclusions. Recent Findings In this review, we outline the principles behind MR, as well as assumptions and limitations of the method. Extensions to the basic approach are discussed, including two-sample MR, bidirectional MR, two-step MR, multivariable MR, and factorial MR. We also consider some new applications and recent developments in the methodology, including its ability to inform drug development, automation of the method using tools such as MR-Base, and phenome-wide and hypothesis-free MR. Summary In conjunction with the growing availability of large-scale genomic databases, higher level of automation and increased robustness of the methods, MR promises to be a valuable strategy to examine causality in complex biological/omics networks, inform drug development and prioritize intervention targets for disease prevention in the future. INTRODUCTION Causal inference in traditional observational epidemiological studies is hampered by the possibility of confounding and reserve causation [1]. Mendelian randomization (MR) is a method that can be used to uncover casual relationships between an exposure and outcome in the presence of such limitations. MR is a form of instrumental variable analysis, where genetic variants are used as proxies for the exposure of interest [2]. As Mendel’s Laws of Inheritance dictate, alleles segregate randomly from parents to offspring. Thus, offspring genotypes are unlikely to be associated with confounders in the population. In addition, germ-line genotypes are fixed at conception, and therefore, temporally precede the variables under observation, avoiding issues of reverse causation. The MR method involves finding genetic variants which are associated with an exposure, and then testing the association between these variants and the outcome. The causal “de-confounded” relationship between exposure and outcome can then be estimated when the necessary conditions are satisfied (Fig. 1a).Fig. 1Design strategies for Mendelian randomization. a Standard MR: The causal relationship between an exposure variable (X) and an outcome (Y) is estimated using genetic variants (Z) as an instrument, regardless of the presence of variables (C) that may confound the observational association between the exposure and outcome. One method of estimation involves calculation of the Wald Ratio, [see Burgess review paper for description of the various instrumental variable (IV) estimators available] [3], where the causal estimate (\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$ {\widehat{\beta}}_{IV} $$\end{document}β^IV) is derived by dividing the estimated regression coefficient of the outcome on the single nucleotide polymorphism (SNP) (\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$ {\widehat{\beta}}_{YZ} $$\end{document}β^YZ) by the estimated regression coefficient of the exposure on the SNP (\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$ {\widehat{\beta}}_{XZ} $$\end{document}β^XZ). b Two-sample MR. c Bidirectional MR. d Mediation and two-step MR. e Multivariable MR. f Factorial MR In understanding how MR works, it can be useful to think of an MR study as being analogous to a randomized controlled trial (RCT), except that genotypes are used to randomize participants into different levels of the exposure/treatment. However, it is important to realize that this analogy is not perfect e.g., RCTs typically involve treatments over a short duration, whereas an individual’s genetics influences their biology from conception, meaning that many causal estimates from MR studies might reflect life-long exposures as well as developmental compensation that may arise from inheriting these mutations [4••]. Although initial applications of MR mostly focused on estimating the causal effect of environmental exposures on medically relevant outcomes, in recent years MR has found utility across a wide range of domains including the development of pharmaceutical agents (i.e., drug target validation, drug target repurposing, and side effect identification) and in the interpretation of high-dimensional omics studies. Table 1 lists several recent studies illustrating how MR has been used successfully across a wide variety of different contexts [5–37•, 106].Table 1Recent Mendelian randomization studiesTypeExposureOutcomeImportanceReferencesDrug target validation HMGCR (statins)MetabolitesMR study suggests that genetic polymorphisms in the HMGCR gene mimic the effect of statins on a wide range of metabolomic measures[5•]Drug target validation NPC1L1 (ezetimibe)CHDMR study suggests that lowering LDL cholesterol level via inhibition of NPC1L1 results in reduced risk of CHD consistent with results from RCTs of the drug ezetimibe which targets this pathway[6•, 7]Drug target validationPCSK9 (evolucumab)CHDGenetic evidence suggests that polymorphisms in the PCSK9 gene are strongly related to LDL cholesterol levels and risk of CHD. Randomized controlled trials have shown that PCSK9 inhibition is associated with decreased LDL cholesterol levels and risk of myocardial infarction in hyperlipidemic individuals. Several agents that target PCSK9 are now FDA approved for the treatment of hyperlipidemia including the monoclonal antibodies evolucumab and alirocumab. Antisense oligonucleotides that target PCSK9 are also in development[8•, 9]Drug target validationCRPCHDDespite serum levels of C-reactive protein having marked clinical utility as a biomarker of inflammation, MR studies have consistently failed to find evidence for a causal effect of serum C-reactive protein on risk of cardio-metabolic disease. These MR studies have potentially saved pharmaceutical companies from developing agents that would be destined to fail in RCTs[10, 11]Drug target validationLp-PLA2 (darapladib)CHDMany resources were spent on trials that showed therapeutic lowering of Lp-PLA2 level does not lower risk of CVD; some MR studies were published before the reporting of RCT results[12, 13]Drug target repurposingIL6 (tocilizumab)CHDRepurposing blockade of the interleukin-6 receptor (tocilizumab) as therapeutic approach to prevention of coronary heart disease[14•]Predicting side effects of drug targets HMGCR (statins)Type 2 diabetesMR studies indicated that the increased incidence of type 2 diabetes among statin users in RCTs was likely to be due to an on-target effect of statins on HMGCR inhibition[15•]Predicting side effects of drug targets PCSK9/PCSK9 inhibitorsType 2 diabetesSuggests PCSK9 inhibition might increase risk of diabetes[16, 17]Public health/clinical practiceAdiposity (BMI and waist–hip ratio)CHDSuggests adiposity causes CHD, heart failure and ischemic stroke. No trial has yet shown this causal relationship[18, 19]Public health/clinical practiceLDL cholesterolDiabetesSuggests LDL cholesterol lowering might generally lead to increased risk of diabetes mellitus, and has potential ramifications for drugs that lower LDL cholesterol level[20]Public health/clinical practiceTriglyceridesCHDMR studies suggest that lowering triglycerides will reduce risk of CHD.[20, 21•, 22]Public health/clinical practiceEducational attainmentCHDMR findings suggest that policy interventions that increase education may reduce the burden of cardiovascular disease[23]Public health/clinical practiceVitamin DMultiple SclerosisMR studies suggest that lowered vitamin D level is causally associated with increased susceptibility to MS.[24, 25]Public health/clinical practiceAlcoholCVDs (including blood pressure, coronary artery calcification, and CHD)Suggests alcohol is harmful to cardiovascular health at all doses of consumption, contrary to decades of observational data[26, 27]Public health/clinical practiceTelomere lengthCancers, cardiovascular diseases, and other diseasesLarge-scale MR study suggests that longer telomeres increase risk for some cancers but reduce risk for some non-neoplastic diseases, including cardiovascular diseases, which highlight the value of MR at a phenome wide scale[28•]Public health/clinical practiceObesity, type 2 diabetes, Metabolic factorsPancreatic CancerMR study suggests a causal